15 May 2018 : Review article
A Review of Induction with Rabbit Antithymocyte Globulin in Pediatric Heart Transplant Recipients
Martin Schweiger1EF*, Andreas Zuckermann2EF, Andres Beiras-Fernandez3EF, Michael Berchtolld-Herz4EF, Udo Boeken5EF, Jens Garbade6EF, Stephan Hirt7EF, Manfred Richter8EF, Arjang Ruhpawar9EF, Jan Dieter Schmitto10EF, Felix Schönrath11EF, Rene Schramm12EF, Uwe Schulz13EF, Markus J. Wilhelm14EF, Markus J. Barten15EFDOI: 10.12659/AOT.908243
Ann Transplant 2018; 23:322-333
Abstract
Pediatric heart transplantation (pHTx) represents only a small proportion of cardiac transplants. Due to these low numbers, clinical data relating to induction therapy in this special population are far less extensive than for adults. Induction is used more widely in pHTx than in adults, mainly because of early steroid withdrawal or complete steroid avoidance. Antithymocyte globulin (ATG) is the most frequent choice for induction in pHTx, and rabbit antithymocyte globulin (rATG, Thymoglobulin®) (Sanofi Genzyme) is the most widely-used ATG preparation. In the absence of large, prospective, blinded trials, we aimed to review the current literature and databases for evidence regarding the use, complications, and dosages of rATG. Analyses from registry databases suggest that, overall, ATG preparations are associated with improved graft survival compared to interleukin-2 receptor antagonists. Advantages for the use of rATG have been shown in low-risk patients given tacrolimus and mycophenolate mofetil in a steroid-free regimen, in sensitized patients with pre-formed alloantibodies and/or a positive donor-specific crossmatch, and in ABO-incompatible pHTx. Registry and clinical data have indicated no increased risk of infection or post-transplant lymphoproliferative disorder in children given rATG after pHTx. A total rATG dose in the range 3.5–7.5 mg/kg is advisable.
Keywords: Antilymphocyte Serum, Heart Transplantation, Pediatrics
In Press
Original article
Physical Activity Levels in Transplant RecipientsAnn Transplant In Press; DOI: 10.12659/AOT.944101
Original article
Implementation and Evaluation of Discharge Planning for Patients Undergoing Umbilical Cord Blood Transplant...Ann Transplant In Press; DOI: 10.12659/AOT.943770
Original article
Long-Term Graft and Patient Survival After Re-TransplantationAnn Transplant In Press; DOI: 10.12659/AOT.943903
Original article
Post-Donation Regret and Anxiety Among Family Living Liver Donors: The Mediating Roles of Family Relationsh...Ann Transplant In Press; DOI: 10.12659/AOT.944176
Most Viewed Current Articles
05 Apr 2022 : Original article
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
12 Jan 2022 : Original article
Risk Factors for Developing BK Virus-Associated Nephropathy: A Single-Center Retrospective Cohort Study of ...DOI :10.12659/AOT.934738
Ann Transplant 2022; 27:e934738
22 Nov 2022 : Original article
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
15 Mar 2022 : Case report
Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...DOI :10.12659/AOT.935860
Ann Transplant 2022; 27:e935860